Skip to main content
SpringerLink
Log in

Vincristine Sulfate Liposome Injection

A Guide to Its Use in Refractory or Relapsed Acute Lymphoblastic Leukemia

  • Adis Drug Clinical Q&A
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Adult patients with acute lymphoblastic leukemia frequently relapse or are refractory to conventional treatments. The vincristine sulfate liposome injection (Marqibo®) encapsulates the drug in a liposome composed of sphingomyelin and cholesterol to improve tumor drug exposure. At a dose of 2.25 mg/m2 once weekly, this formulation was associated with an overall response rate of 35 % in adults with Philadelphia chromosome-negative relapsed or refractory disease. There were no new or unexpected toxicities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Narayanan S, Shami PJ. Treatment of acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol. 2012;81(1):94–102.

    Article  PubMed  Google Scholar 

  2. National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology. NCCN guidelines: acute lymphoblastic leukemia. Version 1.2012. Fort Washington (PA): National Comprehensive Cancer Network; 2012.

  3. Huwyler J, Drewe J, Krahenbuhl S. Tumor targeting using liposomal antineoplastic drugs. Int J Nanomed. 2008;3(1):21–9.

    Article  CAS  Google Scholar 

  4. Webb MS, Harasym TO, Masin D, et al. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer. 1995;72(4):896–904.

    Article  PubMed  CAS  Google Scholar 

  5. Sarris AH, Hagemeister F, Romaguera J, et al. Liposomal vincristine in relapsed non-Hodgkin’s lymphomas: early results of an ongoing phase II trial. Ann Oncol. 2000;11(1):69–72.

    Article  PubMed  CAS  Google Scholar 

  6. Haim N, Epelbaum R, Ben-Shahar M, et al. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer. 1994;73(10):2515–9.

    Article  PubMed  CAS  Google Scholar 

  7. Talon Therapeutics I. Marqibo (vincristine sulfate liposome injection, Optisome™): a novel, targeted, nanoparticle-encapsulated, anti-cancer compound for hematologic cancers. http://www.talontx.com/pipeline.php?divid=marqibo (2012). Accessed 25 Sep 2012.

  8. Rodriguez MA, Pytlik R, Kozak T, et al. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study. Cancer. 2009;115(15):3475–82.

    Article  PubMed  CAS  Google Scholar 

  9. Thomas DA, Sarris AH, Cortes J, et al. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. (Erratum appears in Cancer. 2006; 106(7):1641). Cancer. 2006;106(1):120–7.

    Article  PubMed  CAS  Google Scholar 

  10. Thomas DA, Kantarjian HM, Stock W, et al. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer. 2009;115(23):5490–8.

    Article  PubMed  CAS  Google Scholar 

  11. O’Brien SM, Aulitzky W, Ben Yehuda D, et al. Phase II study of marqibo in adult patients with refractory or relapsed philadelphia chromosome negative (Ph−) acute lymphoblastic leukemia (ALL) (abstract no. 6507). J Clin Oncol. 2010; 28(15 Suppl) Plus oral presentation at the 46th Annual Meeting of the American Society of Clinical Oncology Annual Meeting; 2010 Jun 4–8; Chicago (IL).

  12. Marqibo (vincritine sulfate liposome injection) for intravenous infusion: US prescribing information. South San Franciso (CA): Talon Therapeutics Inc.; 2012.

  13. Cullis PR, Kantarjian H, Appelbaum F, et al. Marqibo (vincristine sulfate liposomes injections, OPTISOMETM) concentrates vincristine in tumor tissue and lymphoid malignancy oriented tissues in tumor-bearing mice (abstract no. 1403 plus poster presentation). Blood. 2007; 110(11).

  14. Krishna R, Webb MS, St Onge G, et al. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther. 2001;298(3):1206–12.

    PubMed  CAS  Google Scholar 

  15. Appelbaum FR, Rosenblum D, Arceci RJ, et al. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood. 2007;109(5):1810–6.

    Article  PubMed  CAS  Google Scholar 

  16. Schiller G, Coutre S, Larson M, et al. VSLI (vincristine sulfate liposomes injection, Marqibo®) “bridging” to potentially curative hematopoetic stem cell transplantation (HSCT) in adults with Philadelphia chromosome negative (Ph−) acute lymphoblastic leukemai (ALL) (abstract no. 6527). J Clin Oncol. 2011;29(15 Suppl).

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Tracy S. Harrison & Katherine A. Lyseng-Williamson

Authors
  1. Tracy S. Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Additional information

The manuscript was reviewed by: G. Schiller, Los Angeles School of Medicine, University of California, Los Angeles (CA), USA

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harrison, T.S., Lyseng-Williamson, K.A. Vincristine Sulfate Liposome Injection. BioDrugs 27, 69–74 (2013). https://doi.org/10.1007/s40259-012-0002-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40259-012-0002-5

Keywords

Search

Navigation